Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Associated Press (02.24.05) - Wednesday, March 02, 2005
Sang-Hun Choe
Cholera kills an estimated 120,000 people a year, primarily in developing countries. Seventy percent of the world's cholera cases are reported in sub-Saharan Africa. The bacterium, spread mainly through contaminated water or food, attacks the intestine, causing severe diarrhea and dehydration.
From December 2003 to January 2004, researchers conducted a mass cholera vaccination in Beira, Mozambique. About 50,000 Beira residents received two doses of the oral vaccine, rBS- WC, given in successive weeks. Though similar campaigns carried out in Bangladesh and Peru have shown promise, the Mozambique trial was the first targeting a population with high HIV prevalence.
Researchers determined that rBS-WC provides 80-90 percent protection from cholera for six months and 50 percent protection for three years, the researchers reported. Previous needle-administered cholera vaccines provided about 50 percent protection for just two months, they said.
"It is remarkable that such a high level of protection was observed in Beira, a population where 30 percent of adults are living with HIV/AIDS," said IVI Director John Clemens.
"This study's results will be crucial as a prelude to introducing cholera vaccine into the public health programs not only of Mozambique, but elsewhere in Africa where cholera is a significant problem," said Francisco F. Songane, Mozambique's former health minister and coauthor of the study.
The full report, "Effectiveness of Mass Oral Cholera Vaccination in Beira, Mozambique," was published in the New England Journal of Medicine (2005;352(8):757-767).
050302
AD050398
Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .